A signature predicting poor prognosis in gastric and ovarian cancer represents a coordinated macrophage and stromal-response. 
TRANSLATIONAL RELEVANCE:
Cancer is a disease involving complex interactions of the tumor cell along with a multitude of other, distinct cell types which comprise the tumor microenvironment. It is this cross-talk that promotes cancer invasion and metastasis. In this study we use a gastric dataset to identify a tumor specific gene signature termed, the stromal response cluster (SRC). This set of coexpressed genes can also be detected in multiple other cancer types and have prognostic significance in the data sets studied. We show that genes in this signature are predominantly expressed in cancer associated stroma. In addition a strong correlation was observed between the SRC and macrophages of the M2 subclass which are known to promote cancer progression. It is conceivable that identifying patients with high expression of the SRC using biopsy samples taken at the time of diagnosis could help identify candidates for adjunct therapies which act by preventing the polarization of M2 macrophages.
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Author Manuscript Published OnlineFirst on March 21, 2014 ; DOI: 10.1158/1078-0432.CCR- Conclusions We show these genes are consistently co-expressed across a range of independent gastric datasets as well as other cancer types suggesting a conserved functional role in cancer. In addition we show that this signature can be a surrogate marker for M2 macrophage activity and has significant prognostic implications in gastric and ovarian high grade serous cancer.
INTRODUCTION
Cancer is characterized by the invasion of malignant cells into surrounding supportive tissue and distant sites [1] . It is well recognized that the consequent tissue deformation leads to an inflammatory host response with elevated levels of infiltrating inflammatory and immune cells [2] . While this host reaction could merely represent a generic response of the host to injury, the genes that control heterotypic cell interactions in wound healing and cancer stroma, are subject to germ line sequence variations [3] [4] [5] [6] [7] [8] suggesting that the tumor microenvironment may vary among patients exhibiting a variety of phenotypic responses. One such response was reported recently suggesting an immunosuppressive role of FAPα (Fibroblast Activation Protein alpha) expressing cells in the tumor stroma that was tumor permissive [9] . that would best respond to an agent targeted against specific stromal components. FAPα expressing cells may be one example as well as TAMs that are thought to promote cancer and interact with both the cancer cells [11, 12] and other stromal cells [13] .
Genomic profiling using gene expression arrays was designed as a discovery tool, aimed at increased insight into the cause and therapy of disease. The approach proved useful to dissect molecular subtypes of malignancies including Diffuse Large B Cell Lymphoma (DLBCL) [14] and solid tumors such as breast cancer [15] and gastric cancer [16] . Gene expression analysis of a whole tumor is the sum of the mRNA contributions from different cell lineages, driven by cell-autonomous genomic changes as well as non-cell autonomous cell-matrix and cell-cell interactions [17] . We previously described a gene expression signature of co-expressed genes exhibiting increased expression in malignant tissue [16, 18, 19] . More recently, we found a highly related signature in a group of ovarian cancer patients, which was associated with the poorest survival in the Australian Ovarian Cancer Study (AOCS) cohort [20] .
In this study we describe the discovery and exploration of a conserved signature of genes derived from gastric cancer. We extended the analysis to include independent gastric data sets [21, 22] as well as a broader group of malignancies including ovarian cancer [20] , colorectal cancer [23] , lung cancer [24] and breast cancer [25] . This novel finding of a conserved signature in diverse epithelial malignancies, the ontology of the genes in this signature (tissue remodeling) and the specific up-regulation of this signature in gastric cancer over the respective premalignant tissues, all suggest this signature reflects a cancer-specific inflammatory response. We therefore termed the signature as "stromal-response" to emphasize that it is a response to the presence of malignant epithelium. Here we examine the factors that potentially control the expression of this gene expression signature and shows, for the first time, data that suggests that this signature arises from the stromal compartment of the cancer and is strongly associated with the presence of M2 polarized macrophages or TAMs.
MATERIALS AND METHODS

Patients and Samples
Patients diagnosed with operable Gastric Cancer (GC) were included in the study as part of a large cohort study where clinical, demographic and surgical pathology information was collected (PMCC cohort; Supplementary Table   S1 ). Histology of specimens was assessed by an independent pathologist (S.L.). Patients were recruited from six metropolitan hospitals in Melbourne with written informed consent. All procedures were ethically approved by individual hospital Institutional Review Boards that was overseen by Peter MacCallum Cancer Centre IRB. Cases of Ovarian Cancer were obtained through the Australian Ovarian Cancer Study (AOCS) as previously described [20] .
Microarray experiments
Fresh frozen tissue was collected at the time of surgery as previously described [16] were profiled. All tissues required pathology evaluation and the minimum acceptable percentage of tumor cells was 60%. Total RNA was isolated by acid phenol extraction (Trizol, Invitrogen) and column chromatography (RNeasy, Qiagen). RNA quantity and quality was assessed by spectrophotometer (Nanodrop Technologies) and Bioanalyser (Agilent Technologies). Microarrays were hybridized using Affymetrix U133+2 chips (Affymetrix) according to the protocol described in the manual. Microarrays were scanned using the Genechip Scanner (Affymetrix). Data has been submitted to GEO (Series GSE51105).
Additional/Validation Microarray datasets
Details of additional and validation data sets are provided in the Supplementary Materials and Methods.
Laser capture microscopy (LCM)
Laser capture microscopy was performed for 4 cases of gastric cancer and 5 cases of ovarian cancer. 10um sections were placed into membrane coated slides (MDS Analytical Technologies) and stained with cresyl violet (Ambion).
Tumor and stromal compartments were identified by a pathologist and individually isolated using laser capture microdisection (LCM; Arcturus Veritas, MDS Analytical Technologies). RNA isolation, quantitation and Affymetrix arrays were run as described for microarray experiments.
In situ hybridization and Immunohistochemistry
Research. 
Statistics
Differential expressed genes between gastric cancer and normal gastric epithelium were identified using empirical Bayes method available in the Rpackage limma. An FDR of 5% was used as the cut-off to select differentially expressed genes. Hierarchical Ordered Partitioning and Collapsing Hybrid (HOPACH) analysis was performed on the gastric dataset using the R statistical package, which builds a hierarchical tree of maximally homogeneous clusters by recursively partitioning a dataset while ordering and collapsing clusters at each level [26] . Eisen's Cluster was used for hierarchical clustering using average linkage [27] . The statistical significance of coexpression of a gene set was computed using a Monte Carlo procedure. The average correlation of the pair-wise correlation of the set of genes was noted.
The average correlation of a randomly selected set of the same number of genes within the same dataset was computed N times. The proportion of times the randomly selected genes had higher of equal correlation to that of the original set is used as the statistical significance of the correlation. GSEA (Gene Set Enrichment Analysis) [28] analyze the data. The mean expression level of the cluster of genes was used to stratify samples into high and low status for that particular cluster. The top and bottom 33% of the samples were classified as high and low respectively.
RESULTS
The stromal-response signature is a set of co-expressed genes that discriminates gastric cancer from benign gastric tissues
We and others have used gene expression profiling to classify cases according to groups of co-expressed gene signatures [14, 16, 19] . Often, such signatures are associated with histopathological and clinical phenotype, such as drug response, metastatic spread or overall survival. In order to employ this information to instruct patient management, further mechanistic insight as to the co-regulation of the signature genes is required. We have expanded on our previously published gene expression profiling of gastric cancers with the addition of an extra 29 tumour samples [16] . All samples in the cohort were reprofiled this time using Affymetrix U133+2 gene chips. The HOPACH [29] method was used to identify "clusters" of genes that are strongly coexpressed within a given dataset; irrespective of the pathology of the sample.
All genes with a cluster membership value <0.3 were disregarded. This left nine major clusters, each including at least 34 genes, which showed significant co-expression with an FDR smaller than 10 -8 (Table 1; see   Supplementary Table S2 for gene lists).
Five of these HOPACH clusters (Clusters 27, 21, 12, 0 and 26) included a significant proportion of genes (over 60% of genes in the cluster) that were In order to confirm that this signature is only expressed in tumor samples, a separate HOPACH analysis was also performed using all normal and premalignant samples in the cohort. None of the clusters generated in this analysis significantly overlapped with cluster 27 (data not shown) suggesting a tumor specific signature which is not seen in normal or inflamed premalignant tissue.
Biological significance of the HOPACH clusters
To gain more biological insight to the mechanism of the co-expression representative ontogenic title to each cluster (Table 1) The input RNA hybridized onto the Affymetrix arrays described in the previous analysis was derived from whole tumor pieces which ultimately included both tumor and stromal compartments. SRC could represent reactive stroma, but could also represent a mesenchymal state of the cancer cells, such as EMT.
For example, the serum response signature of cell lines was originally expected to represent reactive fibroblasts but was later found to be expressed by the epithelial cells [30, 31] . Using species specific expression profiling, we and others found that some genes in stromal reaction signatures are in fact expressed by epithelial cancer cells [32, 33] . (Table S5) .
A heat map was generated showing expression of the SRC genes (cluster 27). Preferential clustering was observed in the stromal fraction for both gastric cancer and ovarian cancer ( Figure 2C ). We then further analyzed the distribution of the 100 unique stromal-response genes with respect to both the epithelial and stromal compartments of GC and OVCA. We observed that most (GC n=38; OVCA n=54) of the SRC genes are predominantly expressed in the GC and OVCA stroma and only 2 or 4 were highly expressed in the epithelium of GC and OVCA respectively ( Figure 2D&E suggesting that they are equally expressed in both compartments and is suggestive of a dynamic interaction at the epithelial-stromal interface (Supplementary Table S6 lists the compartmental location for each gene).
Genes expressed by the epithelial cells which are tightly co-expressed with SRC, serve as evidence that variation in expression of SRC is the product of heterotypic cancer-stroma cross talk [34] .
The stromal-response signature is co-expressed in multiple carcinoma types.
To determine whether each of the clusters is universal across multiple cancer types we interrogated a variety of publically available datasets as outlined in Table 1 . A permutation approach (Monte Carlo Method) was used to compute the likelihood that these clusters of co-expressed genes were also overrepresented in other solid cancers. The datasets we used were: colorectal carcinoma [23] , lung carcinoma [24] , breast carcinoma [25] and two independent gastric carcinoma cohorts [21, 22] . We found that many tumor datasets that are publicly available had few, if any, non-malignant tissue profiled as part of the dataset limiting the number of datasets available for the analysis to determine if the cluster was tumor specific.
Across all cohorts, several clusters including cluster 27, (the SRC) were tightly co-expressed. This general concordance between the cluster ontology and the robustness of each cluster expression in different organ further supports our contention that stromal-response is a robust, universal and consistent aspect of carcinoma gene expression. 
To identify the specific stromal cell types expressing genes from the SRC, we performed in situ hybridization for the SPARC gene on a TMA comprising GC and its premalignant counterparts. SPARC was chosen as it is among the top 50 most significantly differentiated genes between tumor and normal and acted as a surrogate marker for the metagene. Representative images showing SPARC ISH on normal and tumor samples obtained from the same patient are shown in Figure 3A . As expected, staining was predominantly observed in stromal areas and whilst most stromal cell types expressed these genes to varying extents, fibroblast cells were preferentially stained. SPARC ISH was indicative of the stromal-response signature and was highly expressed in stroma juxtaposed to tumor epithelium. SPARC expression was not high in non-malignant stroma despite the presence of significant amounts of stroma in our tissue sections and despite considerable inflammation in nonmalignant tissues. This suggests a tumor specific function for the stromalresponse genes.
The stromal-response signature is correlated with macrophage infiltrates.
Although the stromal-response signature was exceptionally specific and consistent in all gastric cancer cases, the overall degree of expression was nevertheless variable across multiple cases. Across the GC and benign gastric tissues, the expression of SPARC in the microarray and the SPARC ISH signals were highly correlated. We therefore aimed to exploit this variation to determine which stromal cell type most tightly correlates with the overall expression level of the stromal-response signature, which was defined by SPARC ISH as a surrogate of the signature.
Serial sections of the TMA were prepared. One section was stained by ISH for SPARC as described above. The remaining sections were stained with antibodies for specific markers of stromal cell lineages; anti-smooth muscle actin (anti-SMA), anti-CD31, anti-CD45, and anti-CD68 as markers of connective tissue, endothelial, leukocyte and macrophage cells, respectively.
We then correlated between degree of ISH staining for SPARC and abundance of specific cell lineage(s) in the tumor, based on the markers listed above. Figure 3B shows an example of SPARC ISH on a representative tumor sample with IHC stains performed on serial sections for cell markers described. The association of expression of SPARC ISH and cell markers is summarized in Table 2 for all cases, including the non-malignant ones. We find that the expression of the SPARC correlated best with CD31 and CD68 positive cells when assessed using Fisher's exact test (p=3.2x10 -6 and p=3.7x10 -8 , respectively). Indeed, when we assess the tumors specifically then CD68 positive cells demonstrate the most significant association (Table   2 right Based on the results described in Table 2 we investigated whether M1 or M2 macrophages were more highly enriched in samples with high representation of the SRC genes and analyzed our data with respect to previously published M1 and M2 gene signatures [35] . each gene between SRC high and low was determined. A similar analysis was performed for M2 signature genes. The box plot in Figure 3C shows that M2 genes are more positively correlated with SRC high samples (p=0.032).
The absence of M2 genes in the SRC signature can be attributed to the small cellular contribution of macrophages to the overall tumor microenvironment and expected dilution of expression of these genes in the context of the tumor and other stromal components.
In more advanced stages of tumor development, it is generally well accepted that TAMs have an M2 phenotype based on their cytokine secretion profile with high levels of CD163 expression being a key marker. Using the remaning serial section from the TMA we then performed IHC for CD163 and correlated its expression with SPARC ISH as before ( Figure 3D ). Table 2 (lower panels) shows a significant correlation (p=0.002; Fishers exact test) when both normal and tumor samples were considered. . There was no significant correlation of SPARC ISH/CD163 staining in tumors most likely due to a large number of missing data which can be attributed to TMA exhaustion. These results suggest that CD163+ M2 macrophages may be driving the SRC signature. Figure 4C ; p=0.007). We then used the PMCC dataset to show that these survival differences were not associated with the AJCC stage of the patients, which in itself is a known prognostic factor for GC (Table S8 ).
These observations suggest that the metagene which may be driven by M2 polarization has a prognostic effect. Similarly other cancer intrinsic features, such as cell cycle, or other stromal-responses do not appear to be reflective of overall patient survival.
Discussion
Gene signatures derived from gene expression data have previously been used by ourselves and others to diagnose GC [36] , predict patient prognosis [19, 37, 38] and distinguish cancer stage and grade [39] . Indeed, through our collaborators we have previously published on a stromal signature derived from a Singapore cohort and validated on a group of Australian samples from our laboratory [19] . A number of stromal signatures have been described by others in different cancer contexts [30, 31, 40] 
derived from whole tumour mass, it is impossible to exclude the possibility that the genes are expressed by the cancer, and not the stromal cells. We have previously addressed this concern by profiling xenografted human cancer cells grown in a mouse host [33] . Bioinformatic analysis allowed a species specific profiling of both the host and cancer cell within a heterogenous tumour sample, but, such experiments do not confirm that the observation is physiologically relevant in the human patient body. The study described here used a discovery based approach to identify clusters of coexpressed genes specifically co-segregated with gastric cancers in a more comprehensive data set. The most significant cluster in terms of coexpression and number of differentially expressed genes was SRC. We termed this the "stromal-response" cluster as it is rich in genes which appeared to be derived from the stromal elements of the tumor as determined by annotation, ISH and LCM experiments, and was specifically associated in a juxtatumoral microenvironment and is not found in benign conditions. This is a key advantage of our study, which better distinguishes what genes are expressed from what cell types.
The SRC comprises genes that are predominantly involved in the normal process of wound healing. These complex coordinated processes involve extensive intercellular cross-talk between stromal cells (macrophages, endothelial cells, lymphocytes, fibroblasts), and the epithelial cells. Normal wound healing proceeds in three steps, initially mounting an innate immune rejection of foreign invaders, often associated with injury and inflammation [41] [42] [43] . This is followed by proliferation and tissue remodeling. These stages involve angiogenesis [17, 44] , ECM deposition, and stem cell recruitment [17, 45, 46] . Genes involved in the processes of matricellular remodeling, cell movement and angiogenesis are highly represented in the stromal-response cluster supporting the well established paradigm that chronic wounds and/or inflammation are predisposing factors for tumorigenesis [42, 47, 48] .
The multicellular nature of wound healing impairs the identification of a single critical stromal cell that would coordinate this reaction in cancer. In prostate cancer it is recognized that carcinoma associated fibroblasts (CAFs) may influence tumor behavior by encouraging growth of the primary tumor [45] . In models of breast cancer it was found that the stromal components derived from mesenchymal stem cells play an important role in divesting metastatic properties to the primary cancer [49] . Macrophages are known to play a role in cancer development and progression. In the early stages of tumor initiation M1 macrophages are believed to be activated in response to inflammation and illicit Th1/Th17 responses, a pathway which was found to be associated with cluster 26. Tumor associated macrophages (TAMs) are a primary source of EGF in breast cancers [43, 50, 51] and hence putatively growth promoting. Cancer related inflammation, when innate immune cells are mobilized to assist in tumor formation, has recently been described as a tumor enabling consequence which acts in support of the multiple hallmarks of cancer by providing the necessary factors and enzymes to aid invasion, metastasis, angiogenesis and EMT [52] .
Research. Our data showed a strong correlation between SRC expression and the presence of macrophages, more specifically those of the M2 subclass when all samples were considered. This suggests that M2 macrophages may act as a master regulator of the stromal response. There are examples in human cancer where the immune infiltrate in a carcinoma is a beneficial factor and engenders good prognosis. For instance, lymphocytic infiltrates of breast, ovarian and colorectal cancer [41, 53] are all positive prognostic variables. On the other hand, the complex interaction between CAFs and M2 macrophages and tumor cells has been attributed to an increase in cancer cell motility and ultimately in poor prognosis in prostate cancer [54] . Our findings show a ubiquitously expressed signature of genes derived primarily from tumor stroma that appears to have negative prognostic implications for both gastric and ovarian cancer.
It is conceivable that using the stromal-response signature as a marker for M2 activity in patient biopsies provides tangible criteria for the selection of 
